Publications by Dr Suzannah Harnor - ePrints

Browsing publications by Dr Suzannah Harnor.

Newcastle Authors	Title	Year
Duncan Miller Dr Suzannah Harnor Dr Mathew Martin Dr Richard Noble Professor Steve Wedge et al.	Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy	2023
Dr Suzannah Harnor Dr Celine Cano	Advanced approaches of developing targeted covalent drugs	2022
Duncan Miller Tristan Reuillon Dr Lauren Molyneux Dr Tim Blackburn Dr Noel Edwards et al.	Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor	2022
Islam Al-Khawaldeh Dr Christine Basmadjian Dr Cinzia Bordoni Dr Suzannah Harnor Amy Heptinstall et al.	An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)	2021
Dr Ian Hardcastle Dr Ruth Bawn Dr Tim Blackburn Dr Celine Cano Dr Sarah Cully et al.	Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction	2021
Christopher Matheson Christopher Coxon Dr Benoit Carbain Dr Ian Hardcastle Dr Suzannah Harnor et al.	2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase	2020
Dr Brian Ford Dr Shruti Chachra Ahmed Alshawi Alfie Brennan Dr Suzannah Harnor et al.	Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge	2020
Stephanie Myers Duncan Miller Dr Lauren Molyneux Dr Mercedeh Arasta Dr Ruth Bawn et al.	Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4	2019
Dr Simon Hill Dr Michael Dunn Dr Celine Cano Dr Suzannah Harnor Dr Ian Hardcastle et al.	Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification	2018
Dr Celine Cano Dr Suzannah Harnor Dr Elaine Willmore Professor Steve Wedge	Targeting DNA-PK as a Therapeutic Approach in Oncology	2018
Christopher Coxon Dr Suzannah Harnor Dr Mathew Martin Dr Benoit Carbain Emeritus Professor Bernard Golding et al.	Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines	2017
Dr Suzannah Harnor Alfie Brennan Dr Celine Cano	Inhibition of the DNA-Dependent Protein Kinase for Cancer Therapy	2017
Dr Suzannah Harnor James Pickles Dr Celine Cano	Modulation of the DNA-Damage Response by Inhibitors of the Phosphatidylinositol 3-Kinase Related Kinase (PIKK) Family	2017
Dr Suzannah Harnor Alfie Brennan Dr Celine Cano	Targeting DNA-Dependent Protein Kinase for Cancer Therapy	2017
Dr Victorovich Zaytsev James Pickles Dr Suzannah Harnor Dr Alistair Henderson Mohammed Al Yasiri et al.	Concise syntheses of bridged morpholines	2016
Dr Susan Tudhope Dr Yan Zhao Dr Anita Wittner Annalisa Bertoli Santosh Adhikari et al.	Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels	2014
Dr Suzannah Harnor Dr Tommy Rennison Dr Martin Galler Dr Celine Cano Professor Roger Griffin et al.	Synthesis of 3 '-deoxy-3'-fluorothymidine (FLT) 5 '-O-glucuronide: a reference standard for imaging studies with [¹⁸F]FLT	2014
Annalisa Bertoli Santosh Adhikari Dr Suzannah Harnor Dr Yan Zhao Professor John Lunec et al.	Validation studies with small-molecule modulators of the MDM2/MDMX-p53 binding interaction	2014
Dr Emma Haagensen Huw Thomas Ian Wilson Dr Suzannah Harnor Sara Payne et al.	The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [¹⁸F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice	2013